文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

蛋白质组学揭示脓毒症相关急性肾损伤的生物标志物:一项前瞻性多中心队列研究

[Proteomics reveals biomarkers for sepsis-associated acute kidney injury: a prospective multicenter cohort study].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论前瞻性多中心队列提示CST3、β2M、IGFBP4、CFD、CD59可能作为脓毒症相关急性肾损伤的诊断标志物,其中IGFBP4可能预测CRRT需求,但需进一步临床验证。

该前瞻性多中心队列连续纳入台州市5家医院2019年4月至2021年12月的脓毒症患者,按是否发生急性肾损伤分为SA-AKI组与非SA-AKI组,并以同期体检健康者为对照。蛋白质质谱分析发现7个差异表达蛋白:CST3、β2M、IGFBP4、CFI、CFD、CD59、PTGDS,功能富集涉及免疫应答、补体激活、凝血级联和中性粒细胞脱颗粒。外部验证显示CST3、β2M、IGFBP4、CFD、CD59在SA-AKI组与非SA-AKI组间表达差异有统计学意义,预测SA-AKI的AUC分别为0.788、0.723、0.723、0.795、0.836;IGFBP4预测CRRT需求的AUC为0.84。作者认为这些蛋白可能是SA-AKI诊断的潜在标志物,IGFBP4可能是预测SA-AKI患者需CRRT的潜在标志物,但需进一步临床验证。

要点

  • 外部验证中CD59预测SA-AKI的AUC为0.836,CST3为0.788、CFD为0.795,均超过0.7。
  • IGFBP4预测SA-AKI患者是否需要CRRT的AUC为0.84。
  • CST3、β2M、IGFBP4、CFD、CD59在SA-AKI组与非SA-AKI组间表达差异有统计学意义。
  • 蛋白质组学鉴定出7个差异表达蛋白,涉及免疫应答、补体激活、凝血级联和中性粒细胞脱颗粒。
  • 作者认为上述蛋白可能是SA-AKI诊断的潜在标志物,但需进一步临床验证。

适用人群与场景

  • 台州市5家医院2019年4月至2021年12月连续纳入的脓毒症患者,按是否发生急性肾损伤分为SA-AKI组与非SA-AKI组。
  • 同期体检健康者作为对照(NC组)。
  • 外部验证从其中一家医院选取脓毒症患者和健康者。

研究设计与关键结果

  • 蛋白质组学分析纳入37例脓毒症患者(19例AKI、18例无AKI)和31例健康者,鉴定出SA-AKI组与非SA-AKI组间显著差异表达的7个蛋白:CST3、β2M、IGFBP4、CFI、CFD、CD59、PTGDS。
  • 功能富集分析显示这些蛋白参与免疫应答、补体激活、凝血级联和中性粒细胞脱颗粒。
  • 外部验证纳入65例脓毒症患者(38例AKI、27例无AKI)和20例健康者,ELISA显示CST3、β2M、IGFBP4、CFD、CD59在SA-AKI组与非SA-AKI组间表达差异有统计学意义。
  • ROC曲线分析显示CST3、β2M、IGFBP4、CFD、CD59预测SA-AKI的AUC分别为0.788、0.723、0.723、0.795、0.836,均超过0.7。
  • 进一步分析接受与未接受CRRT的患者,IGFBP4预测价值良好,AUC为0.84。

证据类型、等级与局限

  • 证据类型:前瞻性多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为CST3、β2M、IGFBP4、CFD、CD59可能是SA-AKI诊断的潜在生物标志物。
  • 作者认为IGFBP4可能是预测SA-AKI患者需CRRT的潜在生物标志物。
  • 作者指出上述标志物需进一步临床验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To identify and validate novel biomarkers for the early diagnosis of sepsis-associated acute kidney injury (SA-AKI) and precise continuous renal replacement therapy (CRRT) using proteomics.

METHODS: A prospective multicenter cohort study was conducted. Patients with sepsis admitted to five hospitals in Taizhou City of Zhejiang Province from April 2019 to December 2021 were continuously enrolled, based on the occurrence of acute kidney injury (AKI). Sepsis patients were divided into SA-AKI group and non-SA-AKI group, and healthy individuals who underwent physical examinations during the same period were used as control (NC group). Peripheral blood samples from participants were collected for protein mass spectrometry analysis. Differentially expressed proteins were identified, and functional enrichment analysis was conducted on these proteins. The levels of target proteins were detected by enzyme linked immunosorbent assay (ELISA), and the predictive value of target protein for SA-AKI were evaluated by receiver operator characteristic curve (ROC curve). Additionally, sepsis patients and healthy individuals were selected from one hospital to externally verify the expression level of the target protein and its predictive value for SA-AKI, as well as the accuracy of CRRT treatment.

RESULTS: A total of 37 patients with sepsis (including 19 with AKI and 18 without AKI) and 31 healthy individuals were enrolled for proteomic analysis. Seven proteins were identified with significantly differential expression between the SA-AKI group and non-SA-AKI group: namely cystatin C (CST3), β 2-microglobulin (β 2M), insulin-like growth factor-binding protein 4 (IGFBP4), complement factor I (CFI), complement factor D (CFD), CD59, and glycoprotein prostaglandin D2 synthase (PTGDS). Functional enrichment analysis revealed that these proteins were involved in immune response, complement activation, coagulation cascade, and neutrophil degranulation. ELISA results demonstrated specific expression of each target protein in the SA-AKI group. Additionally, 65 patients with sepsis (38 with AKI and 27 without AKI) and 20 healthy individuals were selected for external validation of the 7 target proteins. ELISA results showed that there were statistically significant differences in the expression levels of CST3, β 2M, IGFBP4, CFD, and CD59 between the SA-AKI group and non-SA-AKI group. ROC curve analysis indicated that the area under the curve (AUC) values of CST3, β 2M, IGFBP4, CFD, and CD59 for predicting SA-AKI were 0.788, 0.723, 0.723, 0.795, and 0.836, respectively, all exceeding 0.7. Further analysis of patients who underwent CRRT or not revealed that IGFBP4 had a good predictive value, with an AUC of 0.84.

CONCLUSIONS: Based on proteomic analysis, CST3, β 2M, IGFBP4, CFD, and CD59 may serve as potential biomarkers for the diagnosis of SA-AKI, among which IGFBP4 might be a potential biomarker for predicting the need for CRRT in SA-AKI patients. However, further clinical validation is required.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhu W, Chen N, Dai H, et al. [Proteomics reveals biomarkers for sepsis-associated acute kidney injury: a prospective multicenter cohort study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41146542. doi:10.3760/cma.j.cn121430-20250317-00253

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。